Rheumatoid Arthritis Clinical Trial
— AIDE-RAPOfficial title:
Effect of Long Term "Anti-inflammatory-diet" Advice in Patients With Rheumatoid Arthritis.
Verified date | February 2022 |
Source | Instituto de Investigación Sanitaria Aragón |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The current study pretends to clarify, whether or not a healthy anti inflammatory diet improves different health-related outcomes in participants with rheumatoid arthritis.
Status | Completed |
Enrollment | 29 |
Est. completion date | June 19, 2018 |
Est. primary completion date | October 19, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Rheumatoid arthritis patients Exclusion Criteria: Any additional pathology or situation that could be considered, according to clinical criteria, of risk for the patient or for the study. for example: - Chronic renal failure - Liver failure - Heart failure - Pregnancy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jose manuel Lou Bonafonte | Centro de Investigación Biomédica en Red de la Obesidad y Nutrición. ISCIII, Hospital San Jorge (Huesca), Instituto Agroalimentario de Aragón (IA2)., Universidad de Zaragoza |
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008 Oct;67(10):1360-4. doi: 10.1136/ard.2008.091454. — View Citation
ISAK. (2011). International Standards For Anthropometric Assessment. International Society for the Advancement of Kinanthropometry.
Siri WE. Body composition from fluid spaces and density: analysis of methods. 1961. Nutrition. 1993 Sep-Oct;9(5):480-91; discussion 480, 492. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in disease activity | Disease activity is determined by Simplified Disease Activity Index (SDAI) | Day 0, month 4, month 8 and month12. | |
Primary | Changes in disease activity | Disease activity is determined by DAS28 score_ c reactive protein (DAS28-CRP) | Day 0, month 4, month 8 and month12. | |
Primary | Changes in disease activity | Disease activity is determined by DAS28 score_ erythrocyte sedimentation rate (DAS28-ESR) | Day 0, month 4, month 8 and month12. | |
Primary | Changes in disease activity | Disease activity is determined by Clinical Disease Activity Index (CDAI) | Day 0, month 4, month 8 and month12. | |
Primary | Changes in functional capacity | Functional capacity is assessed by the Health Assessment Questionnaire (HAQ). | Day 0, month 4, month 8 and month12. | |
Primary | Changes in self-perceived health | Self-perceived health is evaluated by questionnaire EuroQol-5D-3L (EQ-5D) | Day 0, month 4, month 8 and month12. | |
Primary | Global analysis of the dietary pattern during the intervention (FFQ) | Global analysis of the dietary pattern during the intervention is evaluated by the food frequency questionaire (FFQ) | Month 12. | |
Primary | Detailed analysis of diet. | Detailled analysis of diet is carried out by 24 hour dietary recall 3 days/week. Diet will be analyzed by HD-ENRICA diet analisys software (v17). Data analyzed will be: Energy (Kcal), Proteins (g), Carbohydrates (g), Fats (g), Fibre (g), vitamins (mg), minerals (mg), water (ml). | Day 0, month 4, month 8 and month12. | |
Primary | Changes in Mediterranean Diet Adherence Score (MEDAS) | Changes in MEDAS are carried out by MEDAS. 0 points means no adherence, 14 points means maximal adherence. | Day 0, month 4, month 8 and month12. | |
Primary | Changes in Dietary inflammatory Index (DII) | Dietary inflammatory index are calculated with the information provides by 24 hour dietary recall 3 days/week. | Day 0, month 4, month 8 and month12. | |
Secondary | Changes in self-reported pain, | Participants report weekly self perception about pain, answering to a visual analogical scale where 0 means no pain and 10 is the maximum pain imaginable. | Every week from day 0 and during 12 months. | |
Secondary | Changes in self-reported stiffness. | Participants report weekly self perception about stiffness answering to a scale where 0 means no stiffness and 10 is the maximum stiffness imaginable. | Every week from day 0 and during 12 months. | |
Secondary | Changes in self-reported inflammation | Participants report weekly self perception about inflammation answering to a scale where 0 means no stiffness and 10 is the maximum stiffness imaginable. | Every week from day 0 and during 12 months. | |
Secondary | Changes in Lipidomics profile | Lipidomics profiling will be determined by plasma gas chromatography mass spectrometry (GC/MS). Lipidomics profiling in serum samples will be correlated with lipid intake. | Day 0, month 4, month 8 and month12. | |
Secondary | Changes in cytokines/Interleukins (ILs) | IL-1B, IL-4, IL-6, IL-10, IL-17, TNF-a, MCP1 will be analyzed by multiplex assay. Results will be correlated with Disease activity Indexes/scores. | Day 0, month 4, month 8 and month12. | |
Secondary | Changes in anthropometric mesurements | Participant's height (m) and weight (Kg) will be measured and body mass index (BMI) will be calculated. | Day 0, month 4, month 8 and month12. | |
Secondary | Changes in anthropometric measurements | Body fat percentage (BFP) analyzed by bioelectrical impedance analysis (BIA). | Day 0, month 4, month 8 and month12. | |
Secondary | Changes in anthropometric measurements | Body fat percentage (BFP) analyzed by anthropometric analysis acording to ISAK procedures (international standards for anthropometric assessment ) and using Siri formula where Fat %= [(4,95/density) - 4,5] * 100 | Day 0, month 4, month 8 and month12. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |